![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Clinical Pharmacology Workshop in HIV (and HCV) Presentations on New DAAs (oral HCV drugs in phase 3 development now) by Boehringer Ingelheim, Gilead & BMS, by Janssen for telaprevir
|
|
|
April 22-24 2013 Amsterdam
Reported by Jules Levin
NATAP
14th International Workshop on Clinical Pharmacology of HIV Therapy
April 22-24, 2013
The Netherlands, Amsterdam
EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Digestive Disease Week (DDW)
May 18-21, 2013
Orlando, FL
Bristol-Meyers Squibb R. Bertz Pres.
Janssen Pharmaceuticals K. Bertelsen Pres.
Boehringer Ingelheim J. Kort Pres.
Gilead Sciences A. Mathias Pres.
Meeting summary of the Optimal Use of DAAs in Liver Transplant patients J. Kiser Pres.
![Pharm1.gif](../images/053113/053113-2/Pharm1.gif)
![Pharm2.gif](../images/053113/053113-2/Pharm2.gif)
![Pharm3.gif](../images/053113/053113-2/Pharm3.gif)
![Pharm4.gif](../images/053113/053113-2/Pharm4.gif)
![Pharm5.gif](../images/053113/053113-2/Pharm5.gif)
![Pharm6.gif](../images/053113/053113-2/Pharm6.gif)
![Pharm7.gif](../images/053113/053113-2/Pharm7.gif)
![Pharm8.gif](../images/053113/053113-2/Pharm8.gif)
![Pharm9.gif](../images/053113/053113-2/Pharm9.gif)
![Pharm10.gif](../images/053113/053113-2/Pharm10.gif)
![Pharm11.gif](../images/053113/053113-2/Pharm11.gif)
![Pharm12.gif](../images/053113/053113-2/Pharm12.gif)
![Pharm13.gif](../images/053113/053113-2/Pharm13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|